DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg - (New Product)

Product Description

Valpharma provides a wide range of products which inlcudes DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg for the treatment of hypertension, angina pectoris and some types of arrhythmia.Diltiazem is a nondihydropyridines (non-DHP) calcium channel blocker used in the therapy and prophylaxis of coronary insufficiency, exertional angina, angina at rest, Prinzmetal vasospastic angina and post-infarct status, essential hypertension of mild and moderate grade.)

  • Posology: once daily
  • Dossier: available, including bioequivalence studies vs Mono-Tildiem LP (Sanofi Aventis, France)
  • CPP: available
  • Available for worldwide marketing authorization applications
  • Marketing authorization granted: Belgium, France, Germany, Italy, Luxemburg, Spain, The Netherlands, Tunisia
Please contact us for more information.

Valpharma Group

  • IT
  • 2015
    On CPhI since

Valpharma Group

  • IT
  • 2015
    On CPhI since

More Products from Valpharma Group

  • GLICLAZIDE S.R.  TABLETS 30 mg   -   (New Product)

    Product GLICLAZIDE S.R. TABLETS 30 mg - (New Product)

    Valpharma provides a wide range of products which includes GLICLAZIDE S.R. TABLETS 30 mg for the therapy of maturity onset Diabetes Mellitus (non-insulin-dependant or Type II), where dietary management alone has been  insufficient.Gliclazide is an oral hypoglycemic used for the control of blood glucose in people with Diabetes Mellitus (non-insulin-dependant or Type II). It is used when diet, exercise, and weight reduction have not been found to control blood glucose well enough without medication. Gliclazide increases the amount of insulin released by the pancreas and helps the body use insulin more efficiently.
    • Posology: once daily
    • Dossier: available, including bioequivalence studies vs Diamicron LM (Servier, France)
    • CPP: available
    • Registration underway: Malaysia
    • Marketing authorization granted:  Croatia, France, Spain, Syria, Tunisia, Vietnam, Jordan, Turkey
    Please contact us for more information.
  • ISOSORBIDE-5-MONONITRATE S.R. TABLETS 30 mg - 60 mg   -   (New Product)

    Product ISOSORBIDE-5-MONONITRATE S.R. TABLETS 30 mg - 60 mg - (New Product)

    Valpharma provides a wide range of products which includes ISOSORBIDE-5-MONONITRATE S.R. TABLETS 30 mg - 60 mg to prevent angina attacks associated with coronary artery disease. Isosorbide mononitrate is a nitrate-class drug used in the prophylaxis of angina attacks, in the control of unstable angina pectoris, for the treatment of coronary insufficiency, in the treatment of generalized precordial pain, asymptomatic forms detected by ECG and heart failure.
    • Posology: once / twice daily
    • Dossier: available, including bioequivalence studies vs Imdur (Astra Zeneca)
    • CPP: available
    • Registration underway:  Turkey, Vietnam, Jordan, Singapore, Malaysia
    • Marketing authorization granted: Australia, Bulgaria, Croatia, Denmark, Germany, Greece, Iceland, Italy, Romania, Republic of South Africa, Slovenia, Sweden, The Netherlands, United Kingdom
    Please contact us for more information.
  • MELATONIN S.R. TABLETS 2 mg (Product under development)

    Product MELATONIN S.R. TABLETS 2 mg (Product under development)

    Valpharma provides a wide range of pharmaceutical products among which  MELATONIN S.R TABLETS 2 mg (a product under development).Melatonin S.R. tablets 2 mg is indicated as monotherapy for the short-term treatment of primary insomnia characterized by difficulty in getting to sleep and in keeping to sleep. Melatonin is a hormone found in animals, plants and microbes. In animals, levels of melatonin have a daily cycle. It drives the circadian rhythms of several biological functions. Melatonin is produced in the pineal gland which is outside of the blood–brain barrier. It acts as an hormone and is released into the blood. Melatonin acts on melatonin receptors. It also acts directly because it is a powerful antioxidant, which protects DNA.
    • Posology: once daily
    • Dossier: under preparation
    • Available for future worldwide applications
    Please contact us for more information.

Recommended products